Infusion of reconstituted high-density lipoproteins (rHDL) is being studied in clinical trials as an adjunctive therapy for gram-negative sepsis. Since no data are available on its possible effects in systemic candidiasis, we investigated the effect of rHDL infusion into volunteers on the growth of Candida albicans. C. albicans growth was 10-to 100-fold higher in the plasma of volunteers infused with 80 or 100 mg/kg rHDL than in plasma collected before infusion; administration of 60 mg/kg rHDL had marginal effects. In vitro, the isolated lipoprotein subfractions had a growth-promoting effect on C. albicans. These data suggest potential adverse effects of rHDL if infused into patients with systemic candidiasis. Thus, rHDL infusion into patients with sepsis caused by an unknown microorganism may be contraindicated. Informed consent was obtained from all participants, and the guidelines for sequential ultracentrifugation from fresh EDTA-treated plasma human experimentation of the participating institutions were followed. of healthy volunteers who did not receive rHDL infusion. The Grant support: Royal Netherlands Academy of Arts and Sciences (to B.J.K.).
Despite the availability of new and potent antibiotics, mortal-diasis [6] . In addition, earlier studies have demonstrated that Candida albicans grows better in lipid-containing emulsions ity from gram-negative bacterial sepsis has remained constant during the last 30 -40 years [1] . The lipopolysaccharide (LPS) used for parenteral feeding than it does in standard preparations [7 -9] . These data suggest that a lipid-rich environment pro-component of the gram-negative bacterial cell wall mediates most of the inflammatory actions induced by these microorgan-motes C. albicans growth, and this could be a serious drawback for empirical rHDL treatment. For the present study, we asked isms, and conceptually, its neutralization could have beneficial effects on the outcome. Recent studies have applied reconstitu-whether rHDL infusion into human volunteers leads to increased candidal growth. In addition, we investigated whether ted high-density lipoproteins (rHDL) for binding and neutralization of LPS. It has been shown that rHDL administered freshly isolated human lipoproteins promote the growth of C. albicans in vitro and whether C. albicans grows better in to animals protects against lethal endotoxemia [2] and gramnegative sepsis [3] . In addition, its infusion into humans down-plasma of hyperlipoproteinemic mice than in control plasma. modulates the inflammatory reaction induced by LPS [4] . Because of these effects, it has been suggested to use rHDL infusion as an adjunctive therapy in gram-negative sepsis.
Materials and Methods However, sepsis can be caused by a variety of microorganisms, Infusion of rHDL into human volunteers. Three groups of including gram-negative bacteria, gram-positive bacteria, and four healthy volunteers each were infused with rHDL at varifungi, and on clinical grounds it is often impossible to distinous doses (60, 80, or 100 mg/kg) over a 4-hour period. Blood guish between these causes. Therefore, it is important to know samples were collected just before the infusion (time 0) and whether rHDL infusion would affect the course of sepsis due 4, 12, and 24 hours after the start of the infusion. Plasma to microorganisms other than gram-negative bacteria.
samples from subjects receiving the same dose were pooled Acute disseminated candidiasis is a serious infection, of at each time point and were provided by Dr. Jan Eva Doran which the incidence has increased at least 10-fold during the and Dr. Alphonse Hubsch (ZLB Central Laboratory, Bern, last decade [5] . We have recently shown that hypercholesterol-Switzerland). emia in low-density lipoprotein (LDL) receptor -deficient mice Isolation of the lipoprotein subclasses. LPS-free very-lowincreases the susceptibility of these animals to systemic candidensity lipoprotein (VLDL; final cholesterol concentration, 0.9 mmol/L), LDL (2.0 mmol/L cholesterol), and HDL (0.5 mmol/L cholesterol) subclasses, as well as lipoprotein-depleted plasma (LPDP) (õ0.1 mmol/L cholesterol), were isolated by Animals. Homozygous C57BL/6J mice lacking LDL receptors (LDLR0/0) and wild-type LDLR/// controls were obtained from Jackson Laboratories (Bar Harbor, ME) as mating pairs and bred in our local facility. LDL concentrations { SD in the LDLR0/0 mice were 4.92 { 0.53 mmol/L, compared with 0.35 { 0.11 mmol/L in control LDLR/// mice [11] . Blood was collected on EDTA from 6-to 8-week-old mice, and plasma was obtained for the use in C. albicans growth experiments. LPDP from LDLR0/0 and control animals was prepared by ultracentrifugation, as described above. Plasma isolated from five LDLR0/0 and five LDLR/// control mice was studied in three separate experiments.
C. albicans growth in vitro. C. albicans (American Type Culture Collection 10231; 10 4 cfu/mL) was grown in the pooled plasma of rHDL-infused volunteers, as well as in the various and 48 hours of incubation at 37ЊC, aliquots of 40 mL were plated (Wasp spiral plater; DW Scientific, Shipley, UK) on Sabouraud dextrose agar. After another 24 hours of incubation infusion rates (4 -12 hours) resulted in a significantly increased outgrowth of C. albicans, compared with the outgrowth of the at 37ЊC, the colonies were counted and the growth was expressed as the logarithm of colony-forming units per milliliter.
yeast in plasma obtained before infusion (P õ .05, Kruskal-Wallis test; data not shown). Comparison between groups was done by use of the Mann-Whitney test. The Kruskal-Wallis test was used to compare the Growth of C. albicans in freshly isolated human lipoprotein subclasses. As shown in figure 2A , C. albicans grew better growth curves of C. albicans in depleted and nondepleted murine plasma.
in the lipoprotein emulsions from normal human donors than in lipoprotein-depleted plasma, suggesting that all lipoprotein subfractions are able to either enhance C. albicans growth or
Results
to inactivate fungistatic factors present in plasma. To further investigate these two possibilities, the growth of C. albicans Growth of C. albicans in plasma of volunteers infused with rHDL. The total cholesterol and HDL concentrations in the was investigated in plasma of LDLR0/0 mice. Growth of C. albicans in plasma from hyperlipoproteinemic group receiving 60 mg/kg rHDL increased from a basal level of 3.87 and 0.95 mmol/L, respectively, to 4.63 and 1.03 LDLR0/0 mice. In contrast to plasma collected from human volunteers, murine plasma inhibited the growth of C. albicans mmol/L at the end of the 4-hour infusion interval and to 4.72 and 1.32 mmol/L at 12 hours and 4.30 and 1.58 mmol/L at 24 in vitro. However, this growth inhibition was significantly reduced in plasma from LDLR0/0 mice [6] . After 12 hours of hours after the start of the infusion. The total cholesterol and HDL concentrations in the group receiving 100 mg/kg rHDL incubation of 10 4 cfu of C. albicans in LDLR0/0 plasma, the log colony count { SD was 3.7 { 1.1, versus 3.2 { 0.9 in increased from 3.58 and 1.12 mmol/L, respectively, to 4.38 and 1.30 mmol/L at the end of the 4-hour infusion interval and control plasma, and after 24 hours of incubation, it was 3.4 { 1.3, versus 3.0 { 0.7 in control plasma (P õ .05). To discern to 5.00 and 1.60 mmol/L at 12 hours and 4.50 and 2.33 mmol/L at 24 hours after the start of the infusion.
whether this effect is due to the use of lipoproteins as nutrients or to the binding and neutralization of a candidacidal factor by The control growth is represented by the growth of C. albicans in plasma obtained from volunteers before the start of lipoproteins, we compared the growth curves of C. albicans in lipoprotein-depleted plasma from hyperlipoproteinemic and rHDL infusion (time 0; figure 1 ). Infusion of 60 mg/kg rHDL had little effect on the growth of C. albicans, but C. albicans normal mice. C. albicans grew significantly better in lipoproteindepleted plasma from LDLR0/0 mice than in lipoprotein-grew better in plasma obtained after infusion of 80 or 100 mg/kg rHDL (figure 1). The number of C. albicans colony-depleted plasma from the LDLR/// controls, although both subfractions contained similar amounts of lipoproteins (õ0.01 forming units grown in plasma obtained 24 hours after rHDL infusion was Ç100-fold greater than that grown in control mmol/L cholesterol) after the depletion procedure ( figure 2B) . This suggests that a candidacidal factor may be bound to lipo-plasma. Similarly, infusion of 100 mg/kg rHDL at various / 9c65$$my38 04-06-99 09:10:46 cidas UC: CID tein subfractions and in hyperlipoproteinemic plasma from LDLR0/0 mice. These data are in agreement with our previous findings in hyperlipoproteinemic LDLR0/0 mice, which were more susceptible to disseminated candidiasis because of an increased fungal outgrowth in their organs [6] . Although lipid profiles differ between mice and humans, the results of both studies suggest that hyperlipidemia can have deleterious effects by stimulating C. albicans growth in both species. At least two different mechanisms seem to be responsible for the observed effects. First, in agreement with other reports showing increased growth of C. albicans in lipid emulsions used for parenteral feeding [7, 8] , lipids themselves seem to promote the growth of Candida. Cholesterol may act as a nutrient for C. albicans, as has been demonstrated for other microorganisms, such as Staphylococcus aureus [12] . After infusion of rHDL, natural HDL has to be formed through extraction of cholesterol from cell membranes and other lipoprotein subfractions, since rHDL consists of phospholipids and recombinant apolipoprotein A-1 without cholesterol [2] . This process requires several hours, and this explains the increasing effect of rHDL on C. albicans growth at later time points after infusion. Indeed, the total cholesterol and HDL concentrations were found to be higher 12 and 24 hours after the start of the infusion than at the end of the 4-hour infusion interval.
Second, since the growth of C. albicans was enhanced in lipoprotein-depleted plasma of hyperlipoproteinemic mice, binding and neutralization of candidacidal factors, such as sphingosine [13] , platelet microbicidal protein [14] , or the calprotectin complex [15] , by lipoproteins may contribute to the observed effect. Although no lipoproteins were present in lipoprotein-depleted plasma isolated from either LDLR0/0 or nor- to inhibit the candidastatic capacity of sphingosine [13] . Association of an antimicrobial factor with HDL has been reported for S. aureus [16] , and this may also explain the differences observed between HDL and VLDL effects on C. albicans proteins and extracted together with lipoproteins during the lipoprotein depletion procedure. growth, despite the higher cholesterol content of the VLDL subfraction ( figure 2A ). Infusion of rHDL as adjunctive therapy for presumed gram-Discussion negative infections is currently under investigation in clinical trials. Although infusion with a moderate rHDL regimen (60 The results of the present study show that rHDL infusion (at §80 mg/kg) increases the growth of C. albicans in the plasma mg/kg) seems to have no significant effects on C. albicans growth, higher quantities of rHDL strongly potentiate growth of of human volunteers by 10-to 100-fold, compared with the basal growth curve in their plasma collected before rHDL administra-these organisms. This suggests that rHDL may have significant adverse effects when infused into patients with systemic candi-tion. In contrast, there was no significant difference in the growth of C. albicans in plasma before and after infusion of a moderate diasis, and infusion with rHDL into patients with sepsis caused by an unknown microorganism may be contraindicated. In ad-amount of rHDL (60 mg/kg). Similarly, C. albicans growth was increased in the presence of freshly isolated human lipopro-dition, it has been suggested that a lipid-rich environment po-
